Inhibrx (NASDAQ:INBX – Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Inhibrx to post earnings of ($2.88) per share for the quarter.
Inhibrx Price Performance
Inhibrx stock opened at $12.56 on Friday. The stock’s 50 day moving average price is $13.86 and its 200 day moving average price is $14.54. Inhibrx has a one year low of $10.80 and a one year high of $18.95.
Analysts Set New Price Targets
Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Investors Need to Know About Upcoming IPOs
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- The Most Important Warren Buffett Stock for Investors: His Own
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
